In another phase III clinical trial, sintilimab combined with IBI305 (a bevacizumab biosimilar) and chemotherapy significantly improved PFS among patients with EGFR-mutated nonsquamous NSCLC, which progressed after EGFR-TKI treatment, as compared with chemotherapy alone (6.9 vs. 4.3 months, HR = 0.46, P < 0.0001).115. This evidence concerns the gene EGFR and non-small cell lung carcinoma.